This is a working overview of acetylated peptide, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-07-31. Anything still debated is marked as such rather than presented as settled.
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
| Property | Value | Notes |
|---|---|---|
| Class | Synthetic peptide | 28 residues; not a small-molecule compound |
| Molecular mass | About 3,106 Da | Monoisotopic mass of the unmodified chain |
| N-terminal group | Acetylated serine | Present in both native and synthetic forms |
| Secondary structure | Disulfide-constrained loop | One bridge between two cysteine residues |
| Typical source | Solid-phase synthesis | Early isolates came from bovine thymus extracts |
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
=== Moorosi's Revolt === The Cape government immediately began to undermine the traditional power structures of the Basuto. Under the terms of the Mercantile Law of 1871, trade was restricted to those in possession of a government license. In 1872, it implemented the responsible government system, under which the governor's legislative powers were transferred to the Cape Parliament. The Basuto were neither consulted nor formally informed. They were also barred from participating in the parliament unless they accepted to completely abandon their traditional laws and customs, a condition they deemed unacceptable. From that point on, Letsie I and the Governor's Agent in Basutoland, Colonel Griffith, became embroiled in a power struggle. The Cape-appointed magistrates were given autonomy in enforcing colonial legislation as they saw fit. The magistrates interfered with land disputes, when the Basuto previously held exclusive rights on land allocation. Authority over marriage disputes and disputes between the Basuto and white residents were likewise transferred to magistrates' courts. Basuto prophetesses claimed to have communicated in their dreams with the spirit of Moshoeshoe, who had become increasingly angry with the white man's interference in Basuto affairs. The southern corner of Basutoland was settled by the Baphuthi people. Their chief Moorosi was once a tributary ruler of Moshoeshoe who had reluctantly merged his territory with British Basutoland in 1869.
A band mask is a heavy duty full-face mask with many of the characteristics of a lightweight demand helmet. In structure it is the front section of a lightweight helmet from above the faceplate to below the demand valve and exhaust ports, including the bailout block and communications connections on the sides. This rigid frame is attached to a neoprene hood by a metal clamping band, hence the name. It is provided with a padded sealing surface around the frame edge which is held firmly against the diver's face by a rubber "spider", a multiple strap arrangement with a pad behind the diver's head, and usually five straps which hook onto pins on the band. The straps have several holes so the tension can be adjusted to get a comfortable seal. A band mask is heavier than other full face masks, but lighter than a helmet, and can be donned more quickly than a helmet. They are often used by the standby diver for this reason.
=== Worms === Levamisole was originally used as an anthelmintic to treat worm infestations in both humans and animals. Levamisole works as a nicotinic acetylcholine receptor agonist that causes continued stimulation of the parasitic worm muscles, leading to paralysis. Levamisole has gained prominence among aquarists as an effective treatment for Camallanus roundworm infestations in freshwater tropical fish. Levamisole has been used to treat small ruminant animals since the late 1960s. Levamisole-resistant parasitic worms are common in sheep farms in New Zealand, Uruguay, Paraguay, and Brazil.
Sources: en.wikipedia.org
Cryptogenic organizing pneumonia (COP), formerly known as bronchiolitis obliterans organizing pneumonia (BOOP), is an inflammation of the bronchioles (bronchiolitis) and surrounding tissue in the lungs. It is a form of idiopathic interstitial pneumonia. It is often a complication of an existing chronic inflammatory disease such as rheumatoid arthritis, dermatomyositis, or it can be a side effect of certain medications such as amiodarone. COP was first described by Gary Epler in 1985. The clinical features and radiological imaging resemble infectious pneumonia. However, diagnosis is suspected after there is no response to multiple antibiotics, and blood and sputum cultures are negative for organisms.
Otto Knut Olof Folin (April 4, 1867 – October 25, 1934) was a Swedish-born American chemist who is best known for his groundbreaking work at Harvard University on practical micromethods for the determination of the constituents of protein-free blood filtrates and the discovery of creatine phosphate in muscles.
==== Confessors ==== The veneration of confessors, who died peacefully after a life of heroic virtue, is not as ancient as that of martyrs. It was in the fourth century, as is commonly held, that confessors were first given public ecclesiastical honour, though occasionally praised in ardent terms by earlier Fathers. Individual confessors themselves were sometimes called martyrs. Gregory Nazianzen calls Basil of Caesarea a martyr; John Chrysostom applies the same title to Eustachius of Antioch; Paulinus of Nola writes of Felix of Nola that he won heavenly honours sine sanguine martyr ("A bloodless martyr"); Gregory the Great styles Zeno of Verona as a martyr and Metronius gives to Roterius the same title. Later on, the names of confessors were inserted in the diptychs, and reverence was paid them. Their tombs were honoured with the same title (martyria) as those of the martyrs. It remained true, however, at all times that it was unlawful to venerate confessors without permission of the ecclesiastical authority as it had been so to venerate martyrs.
Sources: en.wikipedia.org
== Stability == The stability of a nanoparticle is a term often used to describe the preservation of a specific, usually size-dependent, property of the particle. It can refer to e.g.: its size, shape, composition, crystalline structure, surface properties or dispersion within a solution. The interfacial layer of a nanoparticle can aid these types of stabilities in different ways. The ligands can bind to the different facets of a nanoparticle, the size and type of which will determine the way the ligands will be ordered. The way the ligands are attached to the particle, ordered disordered or somewhere in between, plays a crucial role in the way different particles will interact. This in turn affects the reactivity of the nanoparticle, which is another way to look at the stability of the particle.
=== Blended malt === Blended malt whisky, formerly called vatted malt or pure malt (terms that are now prohibited in the SWR 2009), is one of the least common types of Scotch: a blend of single malts from more than one distillery (possibly with differing ages). Blended malts contain only single malt whiskies from two or more distilleries. This type must contain no grain whiskies and is distinguished by the absence of the word "single" on the bottle. The age of the vat is that of the youngest of the original ingredients. For example, a blended malt marked "8 years old" may include older whiskies, with the youngest constituent being eight years old. Johnnie Walker Green Label and Monkey Shoulder are examples of blended malt whisky. Starting from November 2011, no Scotch whisky could be labelled as a vatted malt or pure malt, the SWR requiring them to be labelled blended malt instead.
== Multiplayer mods == Age of Chivalry - A multiplayer modification. Players fight for either the Mason Order or Agathian Knights in a fictional medieval environment using swords, spears and many other medieval weapons. The mod was released on September 10, 2007. Age of Chivalry received Mod DB Editor's Choice for 2007. Counter-Strike: Malvinas - A multiplayer first-person shooter modification of Counter-Strike: Source, developed and distributed by Argentine web hosting company Dattatec. The game is set in Stanley, the capital of the Falkland Islands. The objective of the game is same to that of the Counter-Strike series; each round is won by either detonating a bomb or by eliminating all members of the enemy team. The mod prompted strong controversy in the United Kingdom; Dattatec's website was targeted by British hackers on March 27, 2013. Dino D-Day - The game is set in 1942 during World War II. The premise of the game is that Adolf Hitler has resurrected dinosaurs, and players can battle online choosing to serve either the Allied nations or the Nazis. Dystopia - A cyberpunk-themed total conversion, somewhat based on popular role-playing game Shadowrun, that pits Punk mercenaries against corporate security forces in both the physical world and cyberspace. Last release August 23, 2014. Dystopia received the Player's Choice Honorable Mention from Mod DB in 2006, Best Mod for Half-Life 2 during the Independent Games Festival in 2006, and received the "Mod Of The Year - 3rd place" and "Genre Award - Action" for mods of 2005 by Mod DB.
Sources: en.wikipedia.org
Its sequence corresponds to the amino-terminal portion of prothymosin alpha, a larger protein present in many cell types. The isolated 28-residue peptide is a fragment of that protein rather than a separately encoded molecule, and laboratory material is produced by synthesis.
The single bridge between two cysteine residues holds the chain in a folded loop that influences its shape and its behavior in solution. Loss of the bridge through reduction or oxidation shifts chromatographic retention and is tracked during stability work.
It is a defined 28-residue sequence derived from a larger precursor, whereas many other thymic preparations are mixtures of several polypeptides. Its acetylated amino terminus and single disulfide bridge distinguish it chemically from unrelated thymic extracts.
It corresponds to the first 28 amino acids of thymosin beta-4, a larger protein found in many tissues. The fragment is acetylated at its N-terminus and is produced synthetically for research and pharmaceutical use. Synthetic and natural forms share the same sequence.